GB9619074D0 - Composition - Google Patents
CompositionInfo
- Publication number
- GB9619074D0 GB9619074D0 GBGB9619074.9A GB9619074A GB9619074D0 GB 9619074 D0 GB9619074 D0 GB 9619074D0 GB 9619074 A GB9619074 A GB 9619074A GB 9619074 D0 GB9619074 D0 GB 9619074D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
KR1019997002030A KR20000036039A (en) | 1996-09-12 | 1997-09-08 | Controlled Release Dosage Form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile Monohydrochloride |
JP10513352A JP2001500150A (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [R- (Z)]-α- (methoxyimino) -α- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride |
IL12878197A IL128781A0 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride |
CN97199411A CN1235544A (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of R-(Z)-alpha-methoxyimino-alpha-(1-azabicyclo 2,2 oct-c-yl) acetonitrile monohydrochloride |
PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
HU9904401A HUP9904401A3 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride |
PL97332074A PL332074A1 (en) | 1996-09-12 | 1997-09-08 | Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride |
TR1999/00505T TR199900505T2 (en) | 1996-09-12 | 1997-09-08 | |
BR9711734A BR9711734A (en) | 1996-09-12 | 1997-09-08 | Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride |
CZ99832A CZ83299A3 (en) | 1996-09-12 | 1997-09-08 | Dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyklo[2,2,2]okt-3-yl)acetonitrile monohydrochloride with controlled release |
AU41288/97A AU724086B2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride |
EP97939064A EP0929301A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2]oct-3-yl)acetonitrile monohydrochloride |
NZ334268A NZ334268A (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride |
CA002265661A CA2265661A1 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl)acetonitrile monohydrochloride |
CO97052280A CO5031291A1 (en) | 1996-09-12 | 1997-09-09 | PHARMACEUTICAL COMPOSITION |
MA24792A MA24359A1 (en) | 1996-09-12 | 1997-09-10 | PROCESS FOR THE NEW FORMULATION OF MONOCHLORHYDRATE OF [R- (Z) -alpha- (METHOXYIMINO-ALPHA- (1-AZABICYCLO [2-2-2] OCT-3-YL) -ACETONITRIYLE? |
ZA978133A ZA978133B (en) | 1996-09-12 | 1997-09-10 | Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride |
IDP973137A ID19589A (en) | 1996-09-12 | 1997-09-10 | COMPOSITION |
ARP970104130A AR008176A1 (en) | 1996-09-12 | 1997-09-10 | ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES |
PE1997000805A PE2499A1 (en) | 1996-09-12 | 1997-09-10 | COATING COMPOSITIONS THAT CONTROL RELEASE |
NO991194A NO991194L (en) | 1996-09-12 | 1999-03-11 | Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride |
US09/759,576 US20010003588A1 (en) | 1996-09-12 | 2001-01-12 | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride |
US09/956,617 US6468560B2 (en) | 1996-09-12 | 2001-09-19 | Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride |
US10/229,645 US20030157169A1 (en) | 1996-09-12 | 2002-08-28 | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride |
CN03102977A CN1446535A (en) | 1996-09-12 | 2003-01-23 | Chlorhydric [R(2)-alpha-methoxyimindogen-alpha-(1-dicycloaza [2.2.2] caryl-3-group) acetonitrile control-released dosage form |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9619074D0 true GB9619074D0 (en) | 1996-10-23 |
Family
ID=10799833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9619074.9A Pending GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0929301A2 (en) |
JP (1) | JP2001500150A (en) |
KR (1) | KR20000036039A (en) |
CN (2) | CN1235544A (en) |
AR (1) | AR008176A1 (en) |
AU (1) | AU724086B2 (en) |
BR (1) | BR9711734A (en) |
CA (1) | CA2265661A1 (en) |
CO (1) | CO5031291A1 (en) |
CZ (1) | CZ83299A3 (en) |
GB (1) | GB9619074D0 (en) |
HU (1) | HUP9904401A3 (en) |
ID (1) | ID19589A (en) |
IL (1) | IL128781A0 (en) |
MA (1) | MA24359A1 (en) |
NO (1) | NO991194L (en) |
NZ (1) | NZ334268A (en) |
PE (1) | PE2499A1 (en) |
PL (1) | PL332074A1 (en) |
TR (1) | TR199900505T2 (en) |
WO (1) | WO1998010762A2 (en) |
ZA (1) | ZA978133B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775597B1 (en) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE |
US6451343B1 (en) * | 1998-03-11 | 2002-09-17 | Smithkline Beecham Corporation | Composition for treating dementia and Alzheimer's disease |
DE19918325A1 (en) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
FR2796840B1 (en) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | LOW-DOSE TABLETS AND METHOD OF PREPARATION |
US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
AR040682A1 (en) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
CN100563648C (en) * | 2003-04-25 | 2009-12-02 | 田边三菱制药株式会社 | The Orally administered composition that comprises alkylene dioxybenzene derivative |
ES2273271T5 (en) * | 2003-05-14 | 2013-05-21 | Aptalis Pharma Limited | Composition of controlled release of mechanical stress resistant drug in vivo |
US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
JP2005272347A (en) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | Method for producing solid preparation |
CN101849921A (en) | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | The prolongation release tablet that comprises pramipexole or its officinal salt |
JP4971159B2 (en) | 2004-08-13 | 2012-07-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sustained release pellet preparation containing pramipexole or a pharmaceutically acceptable salt thereof, its production method and use |
EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0392803T3 (en) * | 1989-04-13 | 2004-10-18 | Beecham Group Plc | Hitherto unknown compounds |
GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
AR004178A1 (en) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/en unknown
- 1997-09-08 BR BR9711734A patent/BR9711734A/en unknown
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/en unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 NZ NZ334268A patent/NZ334268A/en unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/en active Pending
- 1997-09-08 CN CN97199411A patent/CN1235544A/en active Pending
- 1997-09-08 IL IL12878197A patent/IL128781A0/en unknown
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/en not_active Application Discontinuation
- 1997-09-08 PL PL97332074A patent/PL332074A1/en unknown
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-09 CO CO97052280A patent/CO5031291A1/en unknown
- 1997-09-10 MA MA24792A patent/MA24359A1/en unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/en not_active Application Discontinuation
- 1997-09-10 ZA ZA978133A patent/ZA978133B/en unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/en unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/en not_active Application Discontinuation
-
1999
- 1999-03-11 NO NO991194A patent/NO991194L/en unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20000036039A (en) | 2000-06-26 |
BR9711734A (en) | 1999-08-24 |
CZ83299A3 (en) | 1999-08-11 |
ID19589A (en) | 1998-07-23 |
AR008176A1 (en) | 1999-12-09 |
JP2001500150A (en) | 2001-01-09 |
WO1998010762A3 (en) | 1998-06-04 |
NO991194D0 (en) | 1999-03-11 |
AU724086B2 (en) | 2000-09-14 |
AU4128897A (en) | 1998-04-02 |
WO1998010762A2 (en) | 1998-03-19 |
HUP9904401A2 (en) | 2000-06-28 |
IL128781A0 (en) | 2000-01-31 |
MA24359A1 (en) | 1998-07-01 |
PL332074A1 (en) | 1999-08-30 |
NO991194L (en) | 1999-03-11 |
HUP9904401A3 (en) | 2001-03-28 |
ZA978133B (en) | 1999-04-12 |
CN1446535A (en) | 2003-10-08 |
CA2265661A1 (en) | 1998-03-19 |
PE2499A1 (en) | 1999-03-24 |
NZ334268A (en) | 2000-10-27 |
CN1235544A (en) | 1999-11-17 |
TR199900505T2 (en) | 1999-06-21 |
CO5031291A1 (en) | 2001-04-27 |
EP0929301A2 (en) | 1999-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2506B1 (en) | Composition | |
GB9624874D0 (en) | Composition | |
GB9600426D0 (en) | Compositions | |
GB9601398D0 (en) | Composition | |
GB9612595D0 (en) | Composition | |
GB9605247D0 (en) | Composition | |
EP0884044A4 (en) | Hairtreatment composition | |
GB9619074D0 (en) | Composition | |
GB9600604D0 (en) | Composition | |
GB9602266D0 (en) | Composition | |
GB9623562D0 (en) | Sachet-packaged compositions | |
GB9620504D0 (en) | Compositions | |
GB9610966D0 (en) | Composition | |
ZA97698B (en) | Composition | |
PL330421A1 (en) | Antiprespirant composition | |
GB9620503D0 (en) | Compositions | |
ZA97146B (en) | Composition | |
GB9611365D0 (en) | Compositions | |
GB9600545D0 (en) | Compositions | |
GB9608390D0 (en) | Composition | |
GB9624211D0 (en) | Composition | |
GB9612493D0 (en) | Composition | |
GB9612026D0 (en) | Composition | |
GB9610768D0 (en) | Composition | |
GB9604945D0 (en) | Composition |